LYRA (Lyra Therapeutics Inc.) Net Profit

Corporate emblem and logo of lyratherapeutics.com (LYRA)

Cash flows for Lyra Therapeutics, Inc. (LYRA) are independent of macroeconomics, relying instead on patents and testing phases. On the GURU.Markets platform, the company's total financial result clearly confirms this trend, where the value is maintained at 0.00. However, the risk of pipeline failure jeopardizes the business, and the delivery of ENT drugs requires strict adherence to sterility and specialized transportation.

LYRA (Lyra Therapeutics) Company Net Income history from 07/04/2022 to 03/28/2026

Financial and market metric breakdowns for Lyra Therapeutics (LYRA)

- price and consensus price forecast:
Stock Quotes Lyra Therapeutics Inc|LYRA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Lyra Therapeutics Inc|LYRA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Lyra Therapeutics|LYRA - Company Book Value|Market-to-Book Ratio lyratherapeutics.com|LYRA - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Lyra Therapeutics, Inc.|LYRA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Lyra Therapeutics Inc.|LYRA - Company Aggregate Debts|Debts to Book Value Lyra Therapeutics Inc|LYRA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lyra Therapeutics|Quick Liquidity lyratherapeutics.com
- net income and valuation multiples indicators:
LYRA - Net Income
Fundamental valuation:LYRA Lyra Therapeutics Inc
Flagship merchandise of Lyra Therapeutics Inc.

This indicator captures the net cash flow remaining within the business after deducting all operating and tax expenses, allowing for an assessment of real value generation efficiency. Analyzing the financial results of the company, the investor sees the current value of 0.00, which for Lyra Therapeutics, Inc. (LYRA) reflects the monetization potential of its patented drug delivery systems and future high margins upon the global scaling of innovative treatment methods.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc - Company Net Income|SCPH: Net Income|Company Net Income Tectonic Therapeutic, Inc.|Tonix Pharmaceuticals (TNXP) - Company Net Income|China SXT Pharmaceuticals, Inc. - Final Profit|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Net Profit BioHarvest Sciences, Inc.|Net Income EXOZ (Invizyne Technologies, Inc.)|ORMP (oramed.com) - Final Profit|Entera Bio - Net Income|Profit After Payment of Taxes HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. - Net Profit|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM: Net Profit|Company Net Income FibroGen Corporation (FGEN)|Company Net Income Telomir Pharmaceuticals|RANI: Final Profit|Net Profit SNYR|Net Profit rallybio.com (RLYB)|Company Net Income Lexaria Bioscience Corp. LEXX|PULM (Pulmatrix Corporation) - Profit After Tax|Pheton - Net Profit|Company Net Income Aptorum Group Limited|IBO (Impact BioMedical Inc) - Net Income|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Net Income YCBD|PRFX (PainReform Corp) - Profit After Payment of Taxes|Net Profit CYTO|Net Financial Result lipella.com|Net Profit OPTN (OptiNose)|PIRS - Net Income|PROC - Company Net Income|Net Financial Result Petros Pharma PTPI|QLI (Qilian International) - Net Income|acelyrin.com - Final Profit|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit